Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $75 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.

June 23, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences and maintained a $75 price target.
The reiteration of an Overweight rating and maintenance of a $75 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Harmony Biosciences. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100